D.E. Shaw & Co
APYX icon

D.E. Shaw & Co’s Apyx Medical APYX Stock Holding History

D.E. Shaw & Co’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-24,586
Closed -$144K – 5165
2022
Q2 		$144K Buy
+24,586
New +$126K ﹤0.01% 4655

Other funds holding APYX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
IP
Invenire Partners Ridgefield, Connecticut $65.4M AUM 18.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

D.E. Shaw & Co's APYX Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Apyx Medical (APYX) in Q3 2022, closing a stake of 24,586 shares — an estimated $144K sold.

D.E. Shaw & Co first reported a position in APYX in Q2 2022 and held it in 1 quarter. The position peaked at $144K in Q2 2022. 54 funds tracked by Wall St. Rank hold APYX as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Apyx Medical position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 24,586 Apyx Medical shares in Q3 2022, an estimated $144K.
  • D.E. Shaw & Co first reported a position in Apyx Medical in Q2 2022 and held it in 1 quarter.
  • D.E. Shaw & Co's Apyx Medical position peaked at $144K in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Apyx Medical as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.